Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous studies have suggested that metformin may be useful for preventing and treating endometrial cancer (EC), while the results have been inconsistent. This systematic review and meta-analysis aimed to investigate the association between metformin use and risk and prognosis of patients with EC. METHODS: PubMed, Embase, and the Cochrane Library databases were searched for observational studies evaluating the effect of metformin on EC prevention or treatment. The odds ratio (OR) was used for analyzing risks, and the hazard ratio (HR) was used for analyzing survival outcomes. A random-effects model was used for data analysis. RESULTS: Seven studies reported data on EC risk. The pooled results suggested that metformin was not significantly associated with a lower risk of EC [OR = 1.05, 95% confidence interval (CI) 0.82-1.35, P = 0.70]. For patients with diabetes, metformin showed no advantage in reducing the EC risk compared with other interventions (OR = 0.99, 95% CI 0.78-1.26, P = 0.95). Further, seven studies were included for survival analysis. The pooled data showed that metformin could significantly improve the overall survival of patients with EC (HR = 0.61, 95% CI 0.48-0.77, P < 0.05) and reduce the risk of EC recurrence (OR = 0.50, 95% CI 0.28-0.92, P < 0.05) Finally, we noted metformin was associated with significantly improving the overall survival of EC patients among diabetes (HR = 0.47; 95%CI 0.33-0.67, P < 0.05). CONCLUSIONS: This meta-analysis did not prove that metformin was beneficial for preventing EC. However, metformin could prolong the overall survival of patients with EC and reduce their risk of cancer relapse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, elevated BG and DM are associated with increased prostate cancer mortality.1775–1777”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1777]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · cited 1×
“Methods Search strategy This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (Additional file 1) [27].”
MethodBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“The publication bias was examined visually by the symmetry of funnel plots and statistically by Egger’s or Begg’s tests [32, 33].”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 2×
“Thus, the between-study results were pooled using the random-effects model proposed by DerSimonian and Laird [30].”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“The heterogeneity between studies was evaluated with Q and I(2) statistics [31].”
MethodWang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
(2014) · Medical Entomology and Zoology · Cited by 17,633
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955 · cited 1×
“The publication bias was examined visually by the symmetry of funnel plots and statistically by Egger’s or Begg’s tests [32, 33].”
MethodParmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802 · cited 1×
“When a study presented only Kaplan– Meier curves, HRs and 95% CIs were calculated based on published methods [29].”
Method
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.11.018 · Cited by 221
Feng, J., Wang, X., Ye, X., Ares, I., Lopez-Torres, B., Martínez, M., Martínez-Larrañaga, M.-R., Wang, X., Anadón, A., & Martínez, M.-A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106114 · Cited by 194
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Concin, N., Creutzberg, C. L., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J. A., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · Virchows Archiv · doi:10.1007/s00428-020-03007-z · Cited by 188
Metadata
- Authors
- Chu, D., Wu, J., Wang, K., Zhao, M., Wang, C., Li, L., & Guo, R.
- Affiliations
- First Affiliated Hospital of Zhengzhou University (CN)
- Corresponding author
- Guo, Ruixia
- Venue
- BMC Cancer
- Published
- 2018-04-18
- Volume
- 18
- Issue
- 1
- Pages
- 438-438
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC5907461
- OpenAlex
- W2805750517
- Cited by
- 90
- References
- 66
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 1 · 2023: 22 · 2022: 20 · 2021: 17 · 2020: 13 · 2019: 8 · 2018: 3
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (31670844)
- Program for Science and Technology Innovation Teams in Universities of Henan Province (17IRTSTHN021)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- metformin, endometrial cancer, cancer risk, tumor recurrence, overall survival, diabetes mellitus, cancer prevention
- MeSH terms
- Female, Humans, Hypoglycemic Agents, Metformin, Neoplasm Recurrence, Local, Prognosis, Proportional Hazards Models, Odds Ratio, Endometrial Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12885-018-4334-5
- The paper
- Chu, D., Wu, J., Wang, K., Zhao, M., Wang, C., Li, L., & Guo, R. (2018). Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-018-4334-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.